Cardiol Therapeutics 주식 (NASDAQ: CRDL)

에 대한 최신 뉴스 Cardiol Therapeutics (NASDAQ:CRDL) 주식

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CRDL

ETWO

HELE

수요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 헬렌 오브 트로이(NASDAQ:HELE)가 개장 전에 분기 이익을 주당 1.04달러, 매출 4억 5824만 달러로 보고할 것으로 예상하고 있다. 헬렌 오브 트로이의 주식은 애프터 마켓에서 2.5% 상승한 63.93달러로 거래되었다.

수요일 주목해야 할 주식: 아즈, 헬렌 오브 트로이, 사라토가 그리고 2종목

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

What if a pimple patch wasn't something to hide? What if it could be a fun, bold accessory? That&#8217;s precisely the concept behind Starface World, the business that turned a basic skincare item into a symbol of self-expression. Since starting in 2019, Starface has grown into a $90 million-a-year business by mixing creative ideas with strong social media skills. Here's how they did it.
<h2 class="wp-block-heading">A New Take on Acne Care</h2>
People have always tried to conceal acne, but Starface took a completely different approach. As a recent CNBC Make It video explains, founders Julie Schott and Brian Bordainick wanted to make growing up – and dealing with acne – a more positive experience. Instead of hiding blemishes, Starface's pimple patches encourage people to embrace them with pride.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Their first product, the yellow Hydro-Star, wasn't just a skincare tool but a fashion statement. These star-shaped patches came in bright, fun packaging and even had a mascot, Big Yellow, who &#8220;came from outer space&#8221; to help people feel better about acne. Starface soon added new colors, special ingredients and even a clear patch for people who wanted something less flashy.
Starface's success lies in its branding. Everything about the company – from its products to its messaging – is designed to <a href="https://www.benzinga.com/content/42533696/gen-z-is-redefining-brand-purpose">appeal to Gen Z</a> and Gen Alpha. The brand's playful tone, vibrant visuals and inclusive message have made it incredibly popular on social media. Platforms like Instagram and TikTok are filled with people proudly showing off their Hydro Stars.
This unique approach has created a sense of community, as owning a Starface product is about more than skincare. The company's message is that it's okay to have acne and to have fun with it.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a>
<h2 class="wp-block-heading">From Hype to Profits</h2>
Starface's focus on self-expression and inclusivity resonated, especially during the pandemic. The brand gained massive traction as people spent more time on Zoom and experimented with self-care. By 2023, Starface had become profitable and sold its products at major retailers like Target, Walmart and CVS.
Today, they sell patches with extra ingredients like tea tree oil and salicylic acid. They've also expanded to Canada and the UK. Despite competing with brands like Hero Cosmetics and Alba Botanica, Starface has built a strong moat around its business by focusing on fun and individuality.
<h2 class="wp-block-heading">Mixed Reviews but Lasting Impact</h2>
Not everyone loves Starface patches as an acne fix. As the CNBC video showed, some customers rave about how they help heal pimples, while others see them as a fun accessory. Either way, the brand's connection with its fans and its message of confidence make it unforgettable.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The market for pimple patches is booming. According to recent research from Spherical Insights, the market valuation is expected to grow from about $500 million to nearly $1 billion by 2033. This shows how much people love these products and how brands like Starface can keep developing new ideas.
With new product launches, including a <a href="https://www.benzinga.com/insights/options/24/12/42515847/check-out-what-whales-are-doing-with-ulta">partnership with Ulta</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) in 2025, Starface shows no signs of slowing down. As long as they keep innovating and staying connected to their audience, their playful and empowering approach to skincare will continue to stand out in the beauty industry.
Starface's rise reminds us of the power of unconventional thinking. Turning a basic skincare product into a lifestyle brand has shown that creativity, strong branding and social media can transform a simple idea into a thriving business.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

ULTA

Thinking Out-Of-The-Box Turned Into A $90 Million/Year Business And Showed The Power Of Strong Branding And Social Media

Ex-President Bill Clinton has been hospitalized in Washington due to a fever on Monday, according to a report.
Clinton was admitted to MedStar Georgetown University Hospital in the afternoon for tests and observation after he developed a fever. Deputy Chief of Staff for the former President, Angel Ureña, shared this news on X. The post was first <a href="https://thehill.com/policy/healthcare/5054369-bill-clinton-hospitalized-fever/">noted</a> on The Hill.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Clinton was admitted to MedStar Georgetown University Hospital this afternoon for testing and observation after developing a fever. He remains in good spirits and deeply appreciates the excellent care he is receiving.
&mdash; Angel Ureña (@angelurena) <a href="https://twitter.com/angelurena/status/1871326214096372135?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ureña said, &#8220;He remains in good spirits and deeply appreciates the excellent care he is receiving.&#8221;
It is worth mentioning that Clinton was previously hospitalized for five days in 2021 due to sepsis caused by an infection, according to The Hill.
See Also: <a href="https://www.benzinga.com/24/12/42637260/elon-musk-accused-of-bullying-republicans-to-scrap-us-china-investment-safeguards-to-protect-teslas-interests?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Accused Of Bullying Republicans To Scrap US-China Investment Safeguards To Protect Tesla&#8217;s Interests</a>
Clinton had been <a href="https://www.benzinga.com/general/politics/24/08/40513316/bill-clinton-contrasts-harris-trump-in-fiery-dnc-speech-we-have-a-clear-choice-we-the-people-ver">actively campaigning</a> for Vice President Kamala Harris throughout the fall. Clinton had made a strong case for Harris during his speech at the Democratic National Convention (DNC).
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Bill Clinton Admitted To Hospital Due To Fever In Washington

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 10 years by 1.29% on an annualized basis producing an average annual return of 12.39%. Currently, Linde has a market capitalization of $201.03 billion. 
Buying $1000 In LIN: If an investor had bought $1000 of LIN stock 10 years ago, it would be worth $3,191.73 today based on a price of $421.00 for LIN at the time of writing.
<h3>Linde's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734997509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Linde 10 Years Ago Would Be Worth Today

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 1.05% on an annualized basis producing an average annual return of 12.15%. Currently, Agnico Eagle Mines has a market capitalization of $39.61 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $330.84 today based on a price of $78.99 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734996621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Agnico Eagle Mines 10 Years Ago Would Be Worth This Much Today

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 6.87% on an annualized basis producing an average annual return of 19.87%. Currently, Goldman Sachs Gr has a market capitalization of $180.39 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $246.87 today based on a price of $571.21 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734994828_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Goldman Sachs Gr 5 Years Ago Would Be Worth Today

WIIM

NEUE

NeueHealth shares are trading higher after the company announced it has entered into an definitive merger to be acquired for $7.33 per share.

NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates ("NEA") at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model.
Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company's existing secured loan facility with Hercules Capital, Inc. will remain in place.
NeueHealth's executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company.

NeueHealth  Entered Into A Definitive Merger Agreement To Be Acquired By An Affiliate Of New Enterprise Associates At An Enterprise Value Of ~$1.3B, Or $7.33/Share In Cash

INSW

International Seaways shares are trading higher after it was announced that the company will join the S&P SmallCap 600 on December 30, 2024.

International Seaways Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) will replace Consolidated Communications Holdings (NASD: CNSL) in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, December 30. Searchlight Capital Partners and British Columbia Investment Management Corporation (BCI) are acquiring Consolidated Communications in a deal expected to be completed soon, pending final closing conditions.

International Seaways To Join S&P SmallCap 600 On Monday, December 30, 2024

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) has outperformed the market over the past 5 years by 3.45% on an annualized basis producing an average annual return of 16.45%. Currently, CBRE Group has a market capitalization of $39.94 billion. 
Buying $100 In CBRE: If an investor had bought $100 of CBRE stock 5 years ago, it would be worth $212.97 today based on a price of $130.51 for CBRE at the time of writing.
<h3>CBRE Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

CREV

Carbon Revolution shares are trading higher after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.

Carbon Revolution plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) (the "Company"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached an agreement with Orion Infrastructure Capital ("OIC") for a further US$25 million financing, which will be released in five tranches, each equal to US$5 million, subject to satisfying certain release conditions. In connection with the release of each of the five tranches of US$5 million, the Company will issue to OIC and the lenders under the US$60 million PIUS loan entered into in May 2023 ("Existing Noteholders"), penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company's shares outstanding.

Financing

Carbon Revolution Has Reached An Agreement With Orion Infrastructure Capital For A Further $25M Financing, Which Will Be Released In 5 Tranches, Each Equal To $5M

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) has outperformed the market over the past 5 years by 36.5% on an annualized basis producing an average annual return of 49.5%. Currently, CrowdStrike Holdings has a market capitalization of $88.93 billion. 
Buying $1000 In CRWD: If an investor had bought $1000 of CRWD stock 5 years ago, it would be worth $7,301.27 today based on a price of $361.06 for CRWD at the time of writing.
<h3>CrowdStrike Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRWD

$1000 Invested In CrowdStrike Holdings 5 Years Ago Would Be Worth This Much Today

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is set to release the highly anticipated second season of "Squid Game" on Dec. 26, adding to an exciting month with its first live NFL games <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41123711/netflix-stock-could-get-boost-from-nfl-games-squid-game-season-2-analyst-says-conte">on Christmas Day.</a>
A Benzinga reader poll shows the second season might face more of an uphill battle for viewers compared to the first season in 2021.
What Happened: Released in September 2021, "Squid Game" <a href="https://www.benzinga.com/general/entertainment/24/12/42305013/squid-game-season-2-includes-new-games-contestant-with-a-crypto-background-revenge-factor-political-overtones">shattered viewership records </a>for Netflix with 1.65 billion hours watched in the first four weeks of availability.
The series became a massive hit and pop culture phenomenon and fans have eagerly been awaiting a second season.
Netflix will premiere all seven episodes of the second season on Dec. 26, beginning at 3 a.m. ET. Benzinga recently polled readers to see how eager people are to watch the new season.
"Will you be watching ‘Squid Game' season 2?" Benzinga asked.
The results were:
<ul>
<li>No, I don't plan to watch: 70%</li>
<li>Yes, I'll binge-watch the entire season when it's out: 21%</li>
<li>Yes, I'll watch each episode as soon as I can: 9%</li>
</ul>
The poll found that Benzinga readers are less excited about the second season compared to the interest generated by the first season.
The day-after-Christmas release could be a double-edged sword for Netflix. While the timing benefits from people being off work, it also coincides with family gatherings that might limit viewership.
Netflix will <a href="https://www.benzinga.com/general/entertainment/24/12/42657482/mrbeast-dominates-prime-video-how-youtuber-could-help-amazon-boost-streaming-presence">also be competing</a> with MrBeast's "Beast Games," a record-breaking game show on Amazon.com's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Prime Video. &#8220;Beast Games&#8221; released its first two episodes on Dec. 19 with a third episode coming on Dec. 26. The show features elements similar to the contests featured in &#8220;Squid Game.&#8221;
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42563662/streamers-max-paramount-won-november-heres-why-analyst-expects-netflix-amazon-to-win-december">Streamers Max, Paramount+ Won November: Here&#8217;s Why Analyst Expects Netflix, Amazon To Win December</a>
What's Next: The second season of "Squid Game" will bring back several cast members from the first season. The new season has already been <a href="https://www.benzinga.com/general/entertainment/24/12/42395178/golden-globes-2025-nominations-netflix-scores-nods-for-emilia-perez-and-squid-game-comcast-lands-4-wicked-noms">nominated for a Golden Globe</a> and could become a favorite on the awards circuit, given more hype around the show this time.
Returning for the second season is the winner of the game in the first season, Seong Gi-hun (aka Player 456), portrayed on screen by&nbsp;Lee Jung-jae.&nbsp;Director and writer&nbsp;Hwang Dong-Hyuk&nbsp;also returns for the second season.
The second season features new characters and revolves around Gi-hun, who returns to the game three years after the competition to search for the people behind it and shut it down for good, as reported by <a href="https://deadline.com/2024/12/squid-game-season-2-explained-hwang-dong-hyuk-lee-jung-jae-1236189235/" target="_blank" rel="noreferrer noopener">Deadline</a>.
This time, characters competing for the prize include a former cryptocurrency influencer who loses a large amount of money for his subscribers and himself. The crypto influencer becomes a fugitive before joining the Squid Game competition, according to the report.
Another one of the 400-plus contestants in the games is a woman who made bad investments following the advice of the same cryptocurrency influencer taking part in the games.
Following the second season, a third and final season of the hit show will be released in 2025. Director Hwang said the second and third seasons were written at the same time and both were produced simultaneously. The third season is currently in the post-production process, the director said.
The first season of "Squid Game" has been watched by a total of 330 million viewers and a total of 2.8 billion hours have been streamed since the release, as reported by <a href="https://variety.com/2024/tv/news/squid-game-viewers-netflix-seoul-experience-1236232449/">Variety</a>. The overall metrics and the first four weeks&#8217; totals for the second season will be used to compare the success of the newest season.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42653325/exclusive-netflix-to-have-merry-christmas-with-nfl-games-will-viewers-tune-in-60-say">EXCLUSIVE: Netflix To Have Merry Christmas With NFL Games, Will Viewers Tune In? 60% Say…</a></li>
</ul>
The study was conducted by Benzinga from Dec. 18 through Dec. 19, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 145 adults.
Photo by DANIEL CONSTANTE on Shutterstock

Entertainment

Exclusives

AMZN

NFLX

EXCLUSIVE: 'Squid Game' Broke Netflix Records, Will Viewers Watch Season 2? 70% Of Benzinga Readers Say…

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.27%. Currently, American Tower has a market capitalization of $87.84 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $10,289.06 today based on a price of $187.97 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734992108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In American Tower 20 Years Ago Would Be Worth This Much Today

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a National Veterinary Associates property for $3.5 million. The property is located in Connecticut and is corporate-operated under a new long-term, triple net lease with annual rent bumps. The transaction was priced at a cap rate in range with previous FCPT transactions.

FCPT

FCPT Announces Acquisition Of A National Veterinary Associates Property For $3.5M

Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.&nbsp; The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem.

Asset Sales

Ashland Signs Definitive Agreement To Sell Avoca Business To Mane; Expected To Close In Q1 2025; No Financial Terms Disclosed

KORE Group Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>)&nbsp;("KORE" or the "Company"), the global pure-play Internet of Things ("IoT") hyperscaler and provider of IoT Connectivity, Solutions, and Analytics, today announced it has received notification (the "Acceptance Letter") from the New York Stock Exchange (the "NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual relating to minimum market capitalization and stockholders' equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from September 12, 2024 (the "Plan Period") to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan. In the Plan, Kore included details regarding previously reported operational restructuring activities, as well as an outlook on the Company's business.&nbsp;

KORE

KORE Announces NYSE Granted The Company An 18-Month Period From September 12, 2024 To Regain Compliance With The Continued Listing Standards

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 12.9%. Currently, Guidewire Software has a market capitalization of $14.36 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $333.15 today based on a price of $173.74 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734991208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

Here's How Much $100 Invested In Guidewire Software 10 Years Ago Would Be Worth Today

Company Priorities for 2025
Looking at both the improvements in the base business and the advances we made with vagus nerve stimulation (VNS), we have a lot to be proud of in 2024.
I am even more pleased we accomplished all of this while slashing our net operating loss by more than 30%.
As we look to 2025,
<ul>
<li>We are exploring new opportunities to increase cash flow generated by the ClearUP business.</li>
<li>We look forward to completing the current work with Feinstein Institute of Bioelectronic Medicine.</li>
<li>We are charting disease-specific clinical trials, moving the company closer to securing regulatory approvals for what we expect will be life-changing treatments for patients in need.</li>
<li>We look forward to talking in more detail about the specific target indications as we advance into the next stage of clinical trial work in 2025.</li>
</ul>
We anticipate that the advancement of our clinical programs for ncVNS will be key to increasing long-term shareholder value. In addition, the board and I continue to evaluate a range of options to maximize shareholder returns, including taking the necessary steps to ensure we regain Nasdaq listing compliance.
I would like to recognize the exceptional efforts of the lean and dedicated Tivic Health team. I thank them for their relentless drive and hard work. Together, with our investors, collaborators, and supporters, we are striving to build a company that can transform the future of medicine and make a lasting, positive impact on the lives of people around the world.
We are excited about the opportunities that lie ahead, and we look forward to continuing this journey with all of you in 2025.
Sincerely,
Jennifer Ernst Chief Executive Officer

Guidance

TIVC

Tivic Health CEO Outlines 2025 Priorities, Sees 30% Reduction in Net Operating Loss, ClearUP Cash Flow Initiatives, ncVNS Clinical Programs To Boost Shareholder Value, Collaboration With Feinstein Institute, And Plans For Nasdaq Compliance

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc., a clinical-stage company specializing in heart disease treatment...

Cardiol Therapeutics Announces Public Share Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage life sciences company, has announced the pricing of ...

Cardiol Therapeutics Sets Common Share Offering Price

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage company specializing in heart disease treatments, ha...

Cardiol Therapeutics Secures $13.5M in Public Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully completed a public offering, raising $15.525 million ...

Cardiol Therapeutics Raises $15.5 Million in Offering

Cardiol Therapeutics (CRDL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Edward Nash...

Cardiol Therapeutics' Strategic Advancements Boost Market Potential and Revenue Projections

Roth MKM analyst Jason Wittes maintained a Buy rating on Cardiol Therapeutics (CRDL – Research Report) today and set a price target of $10.00. The ...

Cardiol Therapeutics (CRDL) Gets a Buy from Roth MKM

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics reports a significant net loss of $28.5 million for the nine months en...

Cardiol Therapeutics Faces Rising Losses and Falling Assets

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has announced promising results from its Phase II MAvERIC-Pilot study,...

Cardiol Therapeutics Reports Promising Phase II Results

Edward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market Potential

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cardiol Therapeutics (CRDL – Research Report) today and set a price target of ...

Vernon Bernardino Issues Buy Rating on Cardiol Therapeutics Following Promising Clinical Results and Strong Financial Position

Press Releases

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

"Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors"

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…

"Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside"

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

APLM

AVCO

BDRX

CRKN

CRNC

CSDX

CTNT

CTOR

GILD

GXAI

HCWB

ILLR

JFBR

KITT

KXIN

NIVF

PDYN

PNPNF

PRSO

QBTS

QMMM

RGTI

RMSG

SHIM

SINT

SPAI

TSX:CRDL

TSXV:PNPN

WLDS

WORX

ZBAO

HC Wainwright & Co.

Roth MKM

Canaccord Genuity

Cantor Fitzgerald

수요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 헬렌 오브 트로이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>)가 개장 전에 분기 이익을 주당 1.04달러, 매출 4억 5824만 달러로 보고할 것으로 예상하고 있다. 헬렌 오브 트로이의 주식은 애프터 마켓에서 2.5% 상승한 63.93달러로 거래되었다.
2. 사라토가 인베스트먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>)는 2분기 실적이 예상보다 좋았다고 발표했다. 이 회사는 주당 1.33달러의 분기 이익을 보고했으며, 이는 애널리스트 예상치인 94센트를 초과한 결과이다. 사라토가 인베스트먼트의 주식은 애프터 마켓에서 8.1% 상승하여 25.50달러로 거래되었다.
3. 애널리스트들은 아즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>)가 분기 이익을 주당 1.32달러, 매출 4억 1,180만 달러로 발표할 것으로 예상하고 있다. 이 회사는 마감 후에 실적을 발표할 예정이다. 아즈의 주식은 애프터 마켓에서 1% 상승하여 81.50달러로 거래되었다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 카디올 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>)는 보통주 공모를 위한 예비 증권 신고서를 발표했다. 그러나 공모 규모는 공개되지 않았다. 카디올 테라퓨틱스의 주식은 애프터 마켓에서 11.7% 하락하여 1.7301달러로 거래되었다.
5. 애널리스트들은 E2오픈 페어런트 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>)가 시장 마감 후에 분기 실적을 주당 5센트, 매출 1억 5482만 달러로 발표할 것으로 예상하고 있다. E2오픈 주식은 애프터 마켓에서 2.5% 상승하여 4.11달러로 거래되었다.
다음 내용을 확인해보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">짐 크래머: AST 스페이스모바일은 &#8216;너무 핫하다&#8217;, 이 기술 주식을 사라고 추천합니다</a></li>
</ul>
사진 출처: Shutterstock

Comments

Cardiol Therapeutics

뉴스

에 대한 최신 뉴스 Cardiol Therapeutics (NASDAQ:CRDL) 주식

수요일, 10월 09, 2024

뉴스

파트너 / 기고자

벤징가 글로벌